Literature DB >> 16830128

[Prospective evaluation of prostate cancer screening in men with a family history of the disease].

T Paiss1, K Herkommer, D Kahn, J E Gschwend, R Küfer, C Maier, W Vogel, J Högel, R E Hautmann.   

Abstract

BACKGROUND: Family history is one of the strongest risk factors for prostate cancer. In this prospective study we evaluated the results of prostate cancer screening performed in healthy brothers of prostate cancer patients. The detection rate of prostate cancer and the positive predictive value of the examinations were determined.
MATERIAL AND METHODS: The study population comprised 513 healthy men who were 38-75 years of age (median 62.0 years). Of these men, 268 having only one affected brother with prostate cancer were assigned to the sporadic group, and 245 probands having 2-10 affected relatives were assigned to the familial group. An abnormal PSA and/or a pathological digital rectal examination (DRE) was noted in 17.5% of familial (43/245) and 15.8% of sporadic probands (35/268). A biopsy of the prostate was performed in 60.5% of familial (26/43) and 71.4% of sporadic (25/35) men with pathological findings.
RESULTS: Prostate cancer was found in 15 of 26 familial (57.7%) and 16 of 25 sporadic (64.0%) probands by prostate biopsy. The overall detection rate was 6.0% (31/513).
CONCLUSION: Due to an increased prevalence the detection rate of prostate cancer and the positive predictive value of PSA and/or DRE are higher in men with a family history as expected in an unselected population. Our data suggest that in predisposed men prostate cancer screening should be recommended early. Furthermore an early indication for prostate biopsy is necessary. This recommendation should also be applied if only one first-degree relative has prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830128     DOI: 10.1007/s00120-006-1056-0

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  8 in total

1.  [Is the prostate cancer screening behaviour of men with familial predisposition predictable?].

Authors:  T Paiss; D Kahn; R Küfer; C Maier; W Vogel; J E Gschwend; R E Hautmann; K Herkommer
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

2.  Prostate cancer screening: results of a prospective trial in Canton Aargau, Switzerland.

Authors:  M Kwiatkowski; A Huber; M Moschopulos; K Lehmann; M Wernli; A Häfeli; F Recker
Journal:  Swiss Med Wkly       Date:  2004-10-02       Impact factor: 2.193

3.  Prostate cancer screening in the Tyrol, Austria: experience and results.

Authors:  W Horninger; A Reissigl; H Rogatsch; H Volgger; M Studen; H Klocker; G Bartsch
Journal:  Eur J Cancer       Date:  2000-06       Impact factor: 9.162

4.  Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.

Authors:  Ingrid W van der Cruijsen-Koeter; André N Vis; Monique J Roobol; Mark F Wildhagen; Harry J de Koning; Theo H van der Kwast; Fritz H Schröder
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

5.  Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994).

Authors:  Stefano Ciatto; Ginetta Gervasi; Rita Bonardi; Paola Frullini; Paola Zendron; Claudio Lombardi; Emanuele Crocetti; Marco Zappa
Journal:  Eur J Cancer       Date:  2005-02       Impact factor: 9.162

6.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

Review 7.  Screening for prostate cancer.

Authors:  Fritz H Schröder
Journal:  Urol Clin North Am       Date:  2003-05       Impact factor: 2.241

8.  [Preventing prostate carcinoma in men with familial disposition].

Authors:  T Paiss; J E Gschwend; C Maier; M Eisele; W Vogel; R E Hautmann; K Herkommer
Journal:  Urologe A       Date:  2002-11       Impact factor: 0.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.